Diabetes, Obesity & Metabolism
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.
Cohort study of 112,596 peopleKidney